title: Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment.
abstract: BACKGROUND
  Whereas specific immunotherapy (SIT) has already been shown to be cost-effective in the treatment of allergic rhinitis compared with symptomatic treatment, only a small number of investigations have compared sublingual (SLIT) and subcutaneous (SCIT) immunotherapeutic approaches. This analysis discusses the cost-effectiveness of SCIT compared with SLIT and a symptomatic treatment modality. At the same time, particular attention is paid to preparation-specific characteristics.
  
  
  METHODS
  The investigation is based on a previously published health economic model calculation. A Markov model, with predefined disease stages and a time period of 9 years, formed the basis of the analysis. The data on specific SCIT (Allergovit®) and SLIT (Oralair®) preparations required for the calculation were adjusted for the present analysis. Quality-adjusted life years (QALYs) based on symptom scores were calculated as the endpoint for effectiveness. Furthermore, the total costs and cost effectiveness of SCIT were determined. Model uncertainties were estimated by means of additional sensitivity analyses.
  
  
  RESULTS
  With regard to effectiveness, both the SCIT and SLIT preparations proved superior compared to symptomatic treatment. Although more expensive, SIT seem to be cost-effective. A direct comparison of SCIT (Allergovit®) and SLIT (Oralair®) showed lower total costs for SCIT treatment over the study period (SCIT 1159 € versus SLIT 1322 €) and improved effectiveness (SCIT 7.112 QALYs versus SLIT 7.060 QALYs).
  
  
  CONCLUSIONS
  SIT represents a cost-effective treatment option for patients with allergic rhinitis compared with symptomatic treatment. The comparison of SCIT (Allergovit®) and SLIT (Oralair®) showed SCIT to be predominant and cost-effective, due in particular to somewhat greater patient compliance and lower drug costs. It also became evident that, as far as possible, product-specific model variables are required for an economic evaluation of SIT treatment.
authors.affiliation: Institute for Social Medicine, Epidemiology, and Health Economics, Charité - Universitätsmedizin Berlin, Luisenstraße 57, 10117 Berlin, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Reinhold
authors.affiliation: Institute for Social Medicine, Epidemiology, and Health Economics, Charité - Universitätsmedizin Berlin, Luisenstraße 57, 10117 Berlin, Germany.|Institute for Health Economy, Steinbeis University Berlin, Berlin, Germany.
authors.forename: Bernd
authors.initials: B
authors.lastname: Brüggenjürgen
keywords: Allergic rhinitis; Cost effectiveness; Model calculation; Specific immunotherapy